PDF herunterladen
Horm Metab Res 2013; 45(03): 252-254
DOI: 10.1055/s-0032-1323843
Short Communication
© Georg Thieme Verlag KG Stuttgart · New York

The α2-Adrenoceptor Antagonist Yohimbine Normalizes Increased Islet Blood Flow in GK Rats: A Model of Type 2 Diabetes

M. Sandberg
1   Department of Medical cell Biology, Uppsala University, Uppsala, Sweden
,
U. Pettersson
1   Department of Medical cell Biology, Uppsala University, Uppsala, Sweden
,
J. Henriksnäs
1   Department of Medical cell Biology, Uppsala University, Uppsala, Sweden
,
L. Jansson
1   Department of Medical cell Biology, Uppsala University, Uppsala, Sweden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 11. April 2012

accepted 30. August 2012

Publikationsdatum:
26. September 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Overexpression of α2A-adrenoceptors contributes to type 2 diabetes in GK rats. We aimed to investigate if α2-adrenoceptor inhibition affected islet blood flow in these rats. Anesthetized GK and Wistar-F rats were given the α2-adrenoceptor inhibitor yohimbine (2.5 mg/kg BW) intravenously. The GK rats had higher blood glucose and serum insulin concentrations than WF rats. Yohimbine affected neither of these values in WF rats, but decreased blood glucose and increased serum insulin concentrations in GK rats. Total pancreatic and islet blood flows, measured with microspheres, were increased in GK when compared to WF rats. Yohimbine affected none of the blood flow values in WF rats, whereas islet blood flow in GK rats was reduced to values similar to those seen in WF rats. Overexpression of α2-adrenoceptors may contribute to the increased islet blood flow seen in GK rats, and may be eligible for pharmacologic intervention.

 

  • References

  • 1 Ahrén B. Diabetologia 2000; 43: 393-410
    CrossrefPubMed
  • 2 Brunicardi FC, Stagner J, Bonner-Weir S, Wayland H, Kleinmann R, Livinston E, Guth P, Menger M, McCuskey R, Intaglietta M, Charles A, Ashley S, Cheung A, IPP E, Gilman S, Howard T, Passaro Jr E. Diabetes 1996; 45: 385-392
    CrossrefPubMed
  • 3 Jansson L, Eizirik DL, Sandler S. Eur J Pharmacol 1989; 161: 79-83
    CrossrefPubMed
  • 4 Jansson L, Sandler S. Endocrinology 1985; 116: 896-900
    CrossrefPubMed
  • 5 Rosengren AH, Jokubka R, Tojjar D, Granjall C, Hansson O, Li D-Q, Nagaraj V, Reinbothe TM, Tuncel J, Eliasson L, Groop L, Rorsman P, Salehi A, Lyssenko V, Luthman H, Renström E. Science 2010; 327: 217-220
    CrossrefPubMed
  • 6 Atef N, Portha B, Penicaud L. Diabetologia 1994; 37: 677-680
    CrossrefPubMed
  • 7 Svensson AM, Abdel-Halim SM, Efendic S, Jansson L, Östenson CG. Eur J Endocrinol 1994; 130: 612-616
    CrossrefPubMed
  • 8 Carlsson PO, Källskog Ö, Bodin B, Andersson A, Jansson L. Ups J Med Sci 2002; 107: 111-120
    CrossrefPubMed
  • 9 Pettersson US, Henriksnas J, Jansson L. Am J Physiol Endocrinol Metab 2009; 297: E490-E494
    CrossrefPubMed
  • 10 Atef N, Ktorza A, Picon L, Penicaud L. Am J Physiol 1992; 262: E736-E740
    PubMed